Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Novel Leucocyte/Thrombocyte Apheresis for Induction of Steroid-Free Remission in Ulcerative Colitis: A Controlled Randomized Pilot Study.

Kruis W, Nguyen P, Morgenstern J, Ramlow W, Dignaß A, Stallmach A, Drebber U.

J Crohns Colitis. 2019 Mar 13. pii: jjz005. doi: 10.1093/ecco-jcc/jjz005. [Epub ahead of print]

PMID:
30863856
2.

Oral budesonide for induction of remission in ulcerative colitis.

Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH.

Cochrane Database Syst Rev. 2015 Oct 26;(10):CD007698. doi: 10.1002/14651858.CD007698.pub3. Review.

PMID:
26497719
3.

Methotrexate for induction of remission in ulcerative colitis.

Chande N, Wang Y, MacDonald JK, McDonald JW.

Cochrane Database Syst Rev. 2014 Aug 27;(8):CD006618. doi: 10.1002/14651858.CD006618.pub3. Review.

PMID:
25162749
4.

Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis.

Yamamoto T, Umegae S, Matsumoto K.

World J Gastroenterol. 2006 Jan 28;12(4):520-5. Review.

5.

Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis.

Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, Iwao Y, Ishi H, Hibi T.

Inflamm Bowel Dis. 2004 May;10(3):251-7.

PMID:
15290920
6.

Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.

Chatzinasiou F, Polymeros D, Panagiotou M, Theodoropoulos K, Rigopoulos D.

Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.

PMID:
27149138
7.

Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results.

Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B.

J Crohns Colitis. 2016 Jul;10(7):812-20. doi: 10.1093/ecco-jcc/jjw032. Epub 2016 Jan 27.

8.

Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study.

Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, Saniabadi A, Matsushita I, Sato Y, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I.

Clin Gastroenterol Hepatol. 2003 Jan;1(1):28-35.

PMID:
15017514
9.

Adsorptive granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial.

Fukunaga K, Yokoyama Y, Kamokozuru K, Nagase K, Nakamura S, Miwa H, Matsumoto T.

Gut Liver. 2012 Oct;6(4):427-33. doi: 10.5009/gnl.2012.6.4.427. Epub 2012 Oct 18.

10.

Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study.

Martín de Carpi J, Vilar P, Prieto G, García Novo MD, Ribes C, Varea V.

J Pediatr Gastroenterol Nutr. 2008 Apr;46(4):386-91. doi: 10.1097/MPG.0b013e31815604e5.

PMID:
18367949
11.

Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study.

Hiwatashi N, Suzuki Y, Mitsuyama K, Munakata A, Hibi T.

J Gastroenterol. 2011 Jan;46(1):46-56. doi: 10.1007/s00535-010-0308-3. Epub 2010 Sep 29.

PMID:
20878425
12.

Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease.

Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB.

J Clin Gastroenterol. 2006 Jul;40(6):482-9.

PMID:
16825929
13.

Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis.

Dignass AU, Eriksson A, Kilander A, Pukitis A, Rhodes JM, Vavricka S.

Aliment Pharmacol Ther. 2010 Jun;31(12):1286-95. doi: 10.1111/j.1365-2036.2010.04295.x. Epub 2010 Mar 11.

14.

Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.

Hyams JS, Davis S, Mack DR, Boyle B, Griffiths AM, LeLeiko NS, Sauer CG, Keljo DJ, Markowitz J, Baker SS, Rosh J, Baldassano RN, Patel A, Pfefferkorn M, Otley A, Heyman M, Noe J, Oliva-Hemker M, Rufo P, Strople J, Ziring D, Guthery SL, Sudel B, Benkov K, Wali P, Moulton D, Evans J, Kappelman MD, Marquis A, Sylvester FA, Collins MH, Venkateswaran S, Dubinsky M, Tangpricha V, Spada KL, Britt A, Saul B, Gotman N, Wang J, Serrano J, Kugathasan S, Walters T, Denson LA.

Lancet Gastroenterol Hepatol. 2017 Dec;2(12):855-868. doi: 10.1016/S2468-1253(17)30252-2. Epub 2017 Sep 20.

15.

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK.

Cochrane Database Syst Rev. 2016 Apr 21;4:CD000543. doi: 10.1002/14651858.CD000543.pub4. Review.

PMID:
27101467
16.

Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study.

Vernia P, Monteleone G, Grandinetti G, Villotti G, Di Giulio E, Frieri G, Marcheggiano A, Pallone F, Caprilli R, Torsoli A.

Dig Dis Sci. 2000 May;45(5):976-81.

PMID:
10795763
17.

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Feagan BG, Macdonald JK.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi: 10.1002/14651858.CD000543.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;4:CD000543.

PMID:
23076889
18.

Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.

Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Fumery M, Roblin X, Reinisch W, Bouhnik Y, Brixi H, Seksik P, Malamut G, Färkkilä M, Coulibaly B, Dewit O, Louis E, Deplanque D, Michetti P, Sarter H, Laharie D; European Crohn's and Colitis Organisation; Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives.

Gastroenterology. 2016 Feb;150(2):380-8.e4. doi: 10.1053/j.gastro.2015.10.050. Epub 2015 Nov 26.

19.

Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.

D'Haens G, Hommes D, Engels L, Baert F, van der Waaij L, Connor P, Ramage J, Dewit O, Palmen M, Stephenson D, Joseph R.

Aliment Pharmacol Ther. 2006 Oct 1;24(7):1087-97.

20.

Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial.

Domènech E, Panés J, Hinojosa J, Annese V, Magro F, Sturniolo GC, Bossa F, Fernández F, González-Conde B, García-Sánchez V, Dignass A, Herrera JM, Cabriada JL, Guardiola J, Vecchi M, Portela F, Ginard D; ATTICA Study Group by the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa [listed at the end of the article] .

J Crohns Colitis. 2018 May 25;12(6):687-694. doi: 10.1093/ecco-jcc/jjy023.

PMID:
29490024

Supplemental Content

Support Center